Background: Since the initial appearance in the 1980s, Enterobacteriaceae producing extended-spectrum b-lactamase (ESBL) have increased in prevalence and emerged as a major antimicrobial-resistant pathogen. The source of these antimicrobial-resistant bacteria in the developed world is an area of active investigation. Methods: A standard internet search was conducted with a focus on the epidemiology and potential sources of ESBL-producing Enterobacteriaceae in the developed world. Results: The last decade has witnessed several major changes in the epidemiology of these bacteria: replacement of TEM and SHV-type ESBLs by CTX-M-family ESBLs, emergence of Escherichia coli ST131 as a prevalent vehicle of ESBL, and spread of ESBL-producing E. coli in the community. The most studied potential sources of ESBL-producing Enterobacteriaceae in humans in the community include food and companion animals, the environment and personto-person transmission, though definitive links are yet to be established. Evidence is emerging that international travel may serve as a major source of introduction of ESBL-producing Enterobacteriaceae into the developed world. Conclusions: ESBL-producing Enterobacteriaceae has become a major multidrug-resistant pathogen in the last two decades, especially in the community settings. The multifactorial nature of its expansion poses a major challenge in the efforts to control them.
Introduction
Antimicrobial resistance constitutes one of the greatest challenges in modern medicine. For the treatment of infections caused by Gram-negative pathogens, the most commonly used classes of antimicrobial agents include fluoroquinolones, cephalosporins and b-lactam/b-lactamase inhibitor combinations thanks to their track records of efficacy, safety and availability in both oral and parenteral formulations. Resistance to these agents would compromise the efficacy of empiric treatment of suspected Gram-negative infections and limit the therapeutic options for their definitive treatment as well.
Extended-spectrum b-lactamases (ESBLs) are b-lactamases that can hydrolyze penicillins and cephalosporins. Therefore, enteric Gram-negative bacteria belonging to the family Enterobacteriaceae become resistant to these classes of b-lactam agents when they acquire an ESBL gene and produce the enzyme. ESBLs are pervasive worldwide, with over 1.5 billion people colonized with ESBL-producing Enterobacteriaceae by one
Classic ESBLs
ESBLs are defined as b-lactamases that are capable of hydrolyzing one or more oxyimino-b-lactams, such as cefotaxime, ceftazidime and aztreonam, at a rate generally >10% of that of benzylpenicillin. 2 In the clinical microbiology laboratory, production of an ESBL by gram-negative bacteria is defined by (i) reduced susceptibility to one or more of the following agents (ceftazidime, cefotaxime, ceftriaxone, cefpodoxime or aztreonam), and (ii) potentiation of the activity of these agents in the presence of clavulanic acid, which is a b-lactamase inhibitor and clinically available as a component of amoxicillin-clavulanic acid.
It had been known for decades that most Klebsiella pneumoniae strains produced SHV-type non-ESBL b-lactamase, and some Escherichia coli strains produced TEM-type non-ESBL b-lactamase. 3 These 'classic' enzymes such as SHV-1 and TEM-1 can hydrolyze ampicillin, but cannot not hydrolyze oxyiminocephalosporins including ceftriaxone, cefotaxime and ceftazidime, which were specifically designed to resist hydrolysis by these enzymes. However, these non-ESBL b-lactamases evolved into ESBLs in the 1980s by acquiring specific amino acid substitutions that altered the substrate specificity to allow for hydrolysis of oxyimino-cephalosporins, thus conferring the bacteria with resistance to these agents. 4 These TEM-and SHV-type ESBLs were typically encoded on transferable plasmids, and primarily found in E. coli and K. pneumoniae, but also in other gram-negative bacteria. In the 1990s, outbreaks of ESBL-producing E. coli and K. pneumoniae were reported from U.S. hospital and nursing homes. 5, 6 These strains produced TEM-and SHV-type ESBLs and were resistant to oxyimino-cephalosporins, and cross-resistance to other classes of agents (e.g. gentamicin, ciprofloxacin, trimethoprim-sulfamethoxazole) was common. Today, SHV-type ESBLs account for just over 10% of ESBLs, mostly found in K. pneumoniae, whereas TEM-type ESBLs have become uncommon in the U.S. 
CTX-M-Group ESBLs
CTX-M-group b-lactamases are a group of ESBLs that are distinct from TEM and SHV ESBLs. As a new family, CTX-M ESBLs were first reported in 1989 in Germany as CTX-M-1 (for cefotaximase-Munich). 8 These enzymes were increasingly reported in the 1990s and, by early 2000s, surpassed TEM and SHV ESBLs as the most frequently identified group of ESBLs. Six groups of CTX-M ESBLs have been recognized: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, CTX-M-25 and KLUC, with each group differing by 10% in amino acid sequence identity, and there are numerous minor variants within the groups. 9 Nonetheless, they share two common attributes: (i) the bla genes encoding these enzymes very likely originated from the chromosome of various species of the genus Kluyvera, which belongs to the family Enterobacteriaceae but rarely causes human infections, and (ii) these ESBLs preferentially hydrolyze cefotaxime over ceftazidime, which is the opposite of TEM and SHV ESBLs. Interestingly, Kluyvera spp. are usually susceptible to cephalosporins despite the possession of chromosomal CTX-M-group genes. These bla CTX-M genes have been captured by mobile genetic elements (MGEs) such as ISEcp1 or ISCR1 and mobilized from the Kluyvera genomes to plasmids in E. coli. Incidentally, some of these MGEs provide active promoter sequences that allow for increased expression of bla CTX-M , thereby conferring clinically relevant level of cephalosporin resistance in E. coli.
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CTX-M-group ESBLs are now by far the most common ESBLs globally, both in the developing and developed worlds, and are found on various plasmid incompatibility groups, but sometimes also integrated into the chromosome. 9 They are produced by species across the family Enterobacteriaceae, with E. coli being the most common host, followed by K. pneumoniae.
The most common CTX-M ESBLs found in humans worldwide are CTX-M-15 which belongs to the CTX-M-1 group, followed by CTX-M-14 belonging to the CTX-M-9 group. 9 In animals, on the other hand, CTX-M-1, which is the canonical enzyme in the CTX-M-1 group, appears to predominate. 11 The other CTX-M groups are more geographically limited, with the CTX-M-2 group commonly reported from South America and Japan, the CTX-M-8 group from South America and the CTX-M-25 group from Israel. 9 Besides the TEM, SHV and CTX-M-group ESBLs, some other groups of ESBLs are sporadically identified, but they remain relatively rare and are not discussed further (e.g. GES, PER and VEB-group ESBLs). 8 Emergence of CTX-M-Producing E. coli ST131 While strains belonging to various clonal lineages of E. coli, K. pneumoniae and other species of Enterobacteriaceae can produce ESBLs, there is a particularly strong association between E. coli sequence type (ST) 131 and production of CTX-Mgroup ESBLs.
12 E. coli ST131 was initially recognized as a common clonal lineage producing CTX-M-15 from several countries in Europe, Asia and North America, around the time when introduction of multilocus sequence typing (MLST) enabled direct molecular epidemiological comparison of strains studied in laboratories from different countries. 13, 14 Further work by
Johnson and colleagues as well as Beaston and coworkers led to the identification of a sub-lineage within ST131, termed H30 or clade C, as the core clone which is resistant to fluoroquinolones and driving the global expansion of CTX-M-producing E. coli in both healthcare and community settings. 15, 16 It is now understood that E. coli ST131 has evolved over many decades, and propagated more recently when it acquired fluoroquinolone resistance in the 1980s and subsequently also bla CTX-M-15 . 17 More recently, E. coli ST131 H30 has been associated with CTX-Mgroup ESBLs other than CTX-M-15, highlighting the dynamic and ongoing evolution of this multidrug-resistant E. coli lineage. 18 E. coli ST131 is predominant in many countries across the developed world, is associated with multidrug resistance and virulence, and has the ability to readily colonize and transmit among human hosts. Therefore it is considered the most significant high-risk clone among ESBL-producing E. coli.
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Burden of ESBL-Producing Enterobacteriaceae in the Developed World
Rates of ESBL production have steadily increased over the last decade for both E. coli and K. pneumoniae in the developed world ( Figure 1 ). The rates of ESBL producers among E. coli urinary strains at U.S. hospitals increased from 7.8% in 2010 to 18.3% in 2014, but this was as high as 27.7% for strains representing hospital-acquired infection in 2014, the majority of which produced CTX-M-15. 20 Co-resistance to non-b-lactam agents was also common, with fluoroquinolone susceptibility generally below 30%. For K. pneumoniae, 16.3% of clinical strains collected from hospitals across U.S. between 2011 and 2013 were ESBL producers, the majority of which produced CTX-M-group ESBLs. 21 This was in contrast to a different but similarly structured surveillance study that reported only 2.5 to 3.4% of K. pneumoniae strains collected between 1997 and 2000 to demonstrate ESBL phenotypes.
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In Europe, the rates of ESBL producers differ significantly for both E. coli and K. pneumoniae depending on the regions, with very low rates observed in Northern European countries and much higher rates seen in Eastern and Southern European countries. 23, 24 Less than 10% of E. coli and K. pneumoniae produce ESBL in Canada, but the rates appear to be increasing. 25 In Japan, the rates of ESBL producers are around 30% in E. coli and 10% in K. pneumoniae when using the rates of cefotaxime resistance as surrogates. 26 The rates are lower in Australia and New Zealand, ranging between 10 and 15% for these species. 27 The ESBL production rates are much lower for outpatients who mostly present with E. coli community-associated strains. Among female outpatients in the U.S. presenting with E. coli urinary tract infection for example, ceftriaxone resistance rates were 3.3% for children, 4.5% for adults age 64 year old and 9.5% for adults age 65 years old in 2012. 28 Among children, the overall prevalence of ESBL production among Enterobacteriaceae increased from 0.26% in 1999-2001 to 0.92% in 2010-2011 at U.S. hospitals. 29 The latter prevalence, when broken down into the healthcare setting, ranged from 0.6% among outpatients to 7.3% among ICU patients. The majority of the strains were E. coli reflecting the most common causative species of infections among children. Also, non-susceptibility (resistance or intermediate resistance) to nonb-lactam agents was common, ranging from 28.8% to nitrofurantoin to 66.1% to trimethoprim-sulfamethoxazole. In addition to hospitalized and community-dwelling patients, another population that merits attention is residents of long-term care facilities (LTCFs). While data remain limited, some recent studies from Europe report high rates of rectal colonization with ESBL-producing Enterobacteriaceae among residents of LTCFs, 30, 31 and this population may also constitute a significant healthcare-associated reservoir of E. coli ST131. 32, 33 Diarrheal illness due to ESBL-producing E. coli remains rare in the developed world and is usually ascribed to recent overseas travel, 34 but association of bla CTX-M-14 with enteroaggregative E. coli ST131 has been suggested in a survey from Japan. 35 
Spread of ESBLs in the Community
In the first decade since the emergence of ESBLs, ESBLproducing Enterobacteriaceae was considered a healthcareassociated problem, as outbreaks of infections by these Figure 1 . Estimated rates of ESBL producers among E. coli clinical isolates. Most of the data were adopted from 'Antimicrobial resistance: global report on surveillance 2014' published by the World Health Organization (http://www.who.int/drugresistance/documents/surveillancereport/en/). Grey indicates countries with insufficient data organisms were occurring in hospitals or other health care facilities such as nursing homes. 36 However, reports on ESBLproducing E. coli infections occurring among patients without previous exposure to health care (such as recent hospitalization, attendance at haemodialysis clinics or receipt of home care) started to appear at the turn of the century. 37 Indeed, this spread and abundance of ESBL-producing E. coli in the community settings is one of the defining features of the epidemiology of ESBLs in the developed world in the 21st century.
The first major evidence of this epidemiological shift was presented by Rodr ıguez-Baño and colleagues, which demonstrated that nearly half of ESBL-producing E. coli infection cases observed at a hospital in Seville, Spain between 2001 and 2002 represented community-onset infections. 33 The risk factors for ESBL production included diabetes mellitus, recent use of fluoroquinolones, and hospital admission within the preceding year. CTX-M was the most predominant ESBL type, followed by TEM and SHV. Similar observations were made around the same time in the United Kingdom, 38 Italy 39 and other countries, all pointing to the emergence of community-associated infections due to CTX-M-producing E. coli. This phenomenon was later observed in the U.S. as well, in North Carolina then across the continental U.S. 40, 41 In the latter study, the majority were ST131 and carried bla CTX-M-15 , demonstrating that E. coli ST131 is a driving force for the spread of ESBL into the community, 40 in addition to hospitals and nursing homes which had been and continue to be their other major ecological niche in humans. 32 
Potential Sources of ESBLs in the Developed World
Intestinal colonization typically precedes the onset of infection by Gram-negative bacteria including ESBL-producing Enterobacteriaceae. 42 The overall annual increase in the prevalence of fecal carriage was estimated to be approximately 5%, which is consistent with the steady rise in the incidence of ESBL-producing Enterobacteriaceae infections. 43 These observations have motivated numerous investigations aimed at identifying the source of ESBL-producing Enterobacteriaceae leading to intestinal colonization with these organisms. Broadly speaking, five sources have been postulated as contributing to this rising prevalence of ESBL-producing Enterobacteriaceae colonization in the developed world ( Figure 2 ).
Food Animals
More than three quarters of all antimicrobial use is in livestock and not humans, administered for treatment of infection (in particular respiratory tract infection and diarrheal disease), prevention of infection and sometimes for the purpose of growth promotion. 44 ESBL-producing Enterobacteriaceae, in particular E. coli and non-typhoidal Salmonella, are commonly identified in food-producing animals in Europe. For example, over 90% of retail poultry meat in southern Spain contained ESBL-producing E. coli in 2010, up from just over 60% in 2007. 45 In the Netherlands, a survey of retail packaged meat products conducted in 2009 showed that almost 80% of chicken samples contained ESBL producers, most of which were E. coli, whereas the rates were much lower in beef and pork. 46 CTX-M-1 was the most common ESBL in both chicken and human isolates. Furthermore, common STs of ESBL-producing E. coli were shared between isolates from meat and stool of patients hospitalized in the same region, with a notable exception of E. coli ST131 which was found only in humans, leading the investigators to conclude that chicken was a plausible source of ESBL genes in humans but perhaps not of E. coli ST131. Similar findings were reported by another group in the Netherlands. 47 However, when some of these human and poultry strains were re-examined using whole genome sequencing, the strains that were previously considered related between animals and humans had numerous single nucleotide polymorphisms (SNPs) suggesting their separate origins. 48 Instead, reconstruction of plasmid sequences showed that a nearly identical plasmid backbone, in this instance of the IncI1 of group, was found in multiple human and poultry strains, suggesting that certain plasmids may serve as carriers of ESBL genes from livestock animals to humans. This notion was further supported by a recent European study where IncI1 plasmids harboring bla CTX-M-1 were commonly identified in animal isolates and were also seen in human E. coli isolates across various STs. 49 Data are much scarcer in the United States, but the rates of contamination by ESBL-producing Enterobacteriaceae appear to be much lower than in Europe. In a survey of retail chicken, turkey, pork and ground beef conducted in Pennsylvania between 2006 and 2007, only one of the chicken samples contained ESBL-producing E. coli. 50 More recently, CTX-M-producing E.
coli was recovered from 7% of retail meat products purchased in three Midwestern states in 2012. 51 However, over 50% of them contained E. coli producing CMY-2, an acquired AmpC-type b-lactamase that confers cephalosporin resistance but is not an ESBL due to the lack of inhibition of its activity by commonly used b-lactamase inhibitors.
Companion Animals
Companion animals are increasingly drawing attention as a potential source, or vector of ESBL-producing Enterobaceriaceae because of their physical proximity and frequent close contacts with their owners. In a surveillance study of diseased dogs and cats across Europe, 1.6% carried ESBL-producing Enterobacteriaceae in stool, most of which harbored bla CTX-M , but included only 2 E. coli ST131 isolates, suggesting that companion animals may be a source of ESBL genes in general but are unlikely to be a major source of this epidemic clone. 52 The ESBL carriage rates were much higher in the Netherlands, with approximately a quarter of Figure 2 . Conceptual scheme of the ecology of ESBL-producing Enterobacteriacae in the developed world dogs screened carrying ESBL-producing Enterobacteriaceae in their stool. 53 Furthermore, when dogs were screened longitudinally over 6 months, again in the Netherlands, over 80% of the dogs carried an ESBL-producing Enterobacteriaceae strain at some point, suggesting that many dog owners are intermittently exposed to these bacteria. ESBL-producing E. coli from cats and dogs belonged to various STs, but carried bla CTX-M genes on plasmids that were common in humans such as IncF and IncI1. 54 In the U.S., 3.1% of diseased dogs and cats carried ESBL-producing E. coli, with the predominance of bla CTX-M-15 harbored on IncF and IncI1 plasmids. 55 Therefore, as with food animals, companion animals may serve as a source of ESBL-encoding plasmids to humans.
Humans
Person-to-person transmission, especially within household, has also been postulated as a means of spread of ESBL-producing Enterobacteriaceae. When family members of patients who had community-acquired infections due to ESBL-producing Enterobacteriaceae were screened for fecal carriage in Spain, 9 of 54 were colonized in the gastrointestinal tract, and 6 of them were colonized with a strain that had identical banding patterns by pulsed-field gel electrophoresis, strongly indicating transmission within households. 56 In the Netherlands, when 84 household members of 74 patients who had ESBL-producing Enterobacteriaceae infection were followed for 18 months with periodic fecal surveillance, more than half of them had ESBLproducing Enterobacteriaceae at some point. 57 An extensive household outbreak of CTX-M-15-producing E. coli ST131 has also been reported from the U.S., where 2 siblings had urinary tract infection and 4 other family members were colonized by the same strain. 58 The limited evidence suggests that, once introduced to households, person-to-person transmission can be a significant means of the spread of ESBL-producing bacteria in the community.
Environment
Environmental contamination with ESBL-producing Enterob acteriaceae is increasingly reported, more in the developing world but also in the developed world. Of particular interest is wastewater, which captures consequence of human activities and has the potential for extensive environmental contamination. In a longitudinal survey of various wastewater sources in France, ESBL-producing E. coli could be recovered from most samples, mostly harboring bla CTX-M , at significantly higher counts in hospital wastewater than community wastewater. 59 Indeed, proportions of ESBL producers among E. coli are consistently higher in hospital effluents than community effluents, likely reflecting the higher rates of ESBL carriage among inpatients over community dwellers and also the difference in the levels of selective pressure from residual antibiotics in wastewater. 60 The STs found in wastewater are also reflective of those common in humans. For example, E. coli ST131 carrying bla CTX-M-15 was the predominant clone among ESBL-producing Enterobacteriaceae recovered from the outflow of a wastewater treatment plant in Czech Republic. 61 Another entity that has been investigated as a potential environmental source of ESBL producers is wildlife, especially birds. In a survey of carcasses of wild birds in the Netherlands, mostly representing aquatic species such as gulls, waterfowl and waders, 12.3% of the fecal samples grew ESBL-producing E. coli, representing various ESBL genes including bla CTX-M , bla SHV and bla TEM . 62 In another study of wild birds, stool of nestlings was collected in Germany and Mongolia. ESBL-producing E. coli was identified in 13.8% and 10.8% of German and Mongolian nestlings of raptors, respectively. Interestingly, the dominant ESBL gene was bla CTX-M-1 in Germany and bla CTX-M-9 in Mongolia, which likely reflected the local epidemiology in humans. 63 Even a higher carriage rate has been reported in gulls in Spain (74.8%) in a study across Europe, which was predominated by E. coli carrying bla CTX-M-1 or bla CTX-M-14 . 64 While the overall contribution is difficult to quantify, birds that can freely migrate between urban and agricultural lands may play a role in the spread of ESBL-producing bacteria across geographic areas and ecological niches.
International Travel
Over 1 billion people cross international borders for tourism alone every year, and the number is expected to grow. In a meta-analysis of studies reporting fecal colonization of healthy individuals with ESBL-producing Enterobacteriaceae, the pooled estimated prevalence of colonization was high across the developing regions: 46% in the West Pacific, 22% in Southeast Asia and 22% in Africa. On the other hand, the colonization prevalence was much lower yet still significant in the developed regions: 4% in Europe and 2% in the Americas. 43 The disparity in the prevalence of carriage of ESBL-producing Enterobacteriaceae in the developing and developed worlds and commoditization of international travel create an opportunity for these organisms to be transported by colonized travelers. The first study to support this hypothesis came from Canada, in which risk factors for community-associated ESBL-producing E. coli infection were investigated. 65 In this study, history of overseas travel was a strong risk factor for such infection (odds ratio [OR], 5.7). In particular, history of travel to India had an extraordinary OR of 145.6. A similarly designed study from the U.S. also singled out travel to India in the past year as a strong risk factor for community-onset ESBL-producing E. coli infection (OR, 14.4). 66 The actual risks of ESBL colonization during travel to the developing world have been estimated in several studies using pre-travel and post-travel fecal screening. The common theme with these studies is the high colonization rates upon returning from India, or more broadly South Asia, ranging up to 70% of returning travelers. [67] [68] [69] [70] Other commonly identified risk factors included traveler's diarrhea, use of antibiotics and length of the trip. Medical tourism, where patients from the developed countries travel to countries with lower medical costs to receive health care such as elective surgeries, may also play a role in the importation of multidrug-resistant bacteria including ESBL-producing ones. 71 However, prolonged carriage after returning to the developed world may be uncommon, with most travelers losing carriage by 3 months after return. 72, 73 Nonetheless, the magnitude of the acquisition risk and the number of travelers make travel to developing countries a highly plausible source of ESBL acquisition in the developed countries.
Conclusions
ESBL-producing Enterobacteriaceae have increased in prevalence and emerged as a major antimicrobial-resistant pathogen in the developed world. This increase has coincided with a shift in the ESBL types (from TEM and SHV to CTX-M group) and spread of ESBL-producing E. coli into the community. Of particular epidemiological concern is dissemination of ESBL-producing E. coli ST131, which is characterized by high rates of co-resistance to fluoroquinolones and other classes of agents. The rapid dissemination of ESBL-producing organisms is likely multifactorial, but potential contributing sources include animals (both food and companion), the environment, importation through travel and direct transmission within households and the community. The steady and continued increase of ESBL-producing Enterobacteriaceae infections and the associated antimicrobial use has a potential to further select for even more resistant pathogens such as carbapenem-resistant Enterobacteriaceae. 
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